Mannkind (MNKD) Notes Payables (2012 - 2025)
Mannkind (MNKD) reported Notes Payables of $36.3 million for Q4 2025, little changed on a QoQ basis from $36.2 million in Q3 2025.
Mannkind (MNKD) has 7 years of Notes Payables data on file, last reported at $36.3 million in Q4 2025.
- Quarterly Notes Payables changed N/A year-over-year to $36.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.3 million (changed N/A YoY) and the FY2025 annual result came in at $36.3 million, changed N/A from the prior year.
- Notes Payables was little changed at $36.3 million in Q4 2025 per MNKD's latest filing, from $36.2 million in the prior quarter.
- Across five years, Notes Payables topped out at $36.3 million in Q4 2025 and bottomed at $36.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.28 Mn |
| Sep 30, 2025 | 36.22 Mn |
| Jun 30, 2025 | 36.17 Mn |
| Mar 31, 2025 | 36.11 Mn |
| Sep 30, 2020 | 45.38 Mn |
| Jun 30, 2020 | 5.39 Mn |
| Mar 31, 2020 | 5.10 Mn |
| Dec 31, 2019 | 5.03 Mn |
| Sep 30, 2019 | 2.52 Mn |
| Jun 30, 2015 | 64.12 Mn |
| Mar 31, 2015 | 99.59 Mn |
| Dec 31, 2014 | 99.36 Mn |
| Sep 30, 2014 | 99.12 Mn |
| Sep 30, 2013 | 114.90 Mn |
| Jun 30, 2013 | 114.74 Mn |
| Mar 31, 2013 | 119.64 Mn |
| Dec 31, 2012 | 114.44 Mn |